Cents and Sensibility - Kimberly and Friends' Consortium Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Cents and Sensibility - Kimberly and Friends' Consortium

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: coissant who wrote (62813)	1/14/2000 10:19:00 AM
From: johnsto1	Read Replies (1) of 108040

LJLB...WILL GO TO 30 EASY WITH VOLUME To: Wes Stevens (25795 ) From: johnsto1 Sunday, Jan 9 2000 11:01PM ET Reply # of 26105 LJLB [LJLBioSystems] I think I found a good one here.The companies products help speed the process of biotech.Revenues up on sales and losses up because of hiring of sales people.It's not a sexy biotech but with a 2.7 float,26% institutionally held,at $8 it could become one.I'm buying Monday. 2 profiles: Capitalization % LT Debt to Total Cap 5% Owned by Institutions 26.2% Market Capitalization 100 Mil Avg Dly Vol (30 days) 31,600 Growth Rates Earnings $ % 5 Yr Hist Latest Qtr. (Sep 99) -.16 up 24% Latest 12 Months -.75 NA NA First Call Consensus Estimate LT Future Current Qtr. (Dec 99) -.16 up 16% Yr. Ended Dec. 99 -.72 up 13% 85% Yr. Ended Dec. 00 -.65 up 10% Revenues 5 Yr Hist Latest Qtr. (Sep 99) 2.6 Mil up 81% Latest 12 Months 7.6 Mil NA NA Dividends 5 Yr Hist Indicated Rate & Yield NA 0% Increases Last 5 Yrs NA NA Key Ratios & Measures 5 Yr. Range Current P/E NM NM Price to Book 2 - 22.5 18.4 Price to Cash Flow NA NM Price to Sales 3.1 - 17.2 13.15 Return on Equity NA NM Beta .99 Business Overview LJL BioSystems, Inc. designs and produces drug discovery products. The drug discovery process involves several stages including assay development, (reading and analyzing how drug compounds perform when tested against biological targets). LJL's proprietary technology platform addresses the throughput limitations of High Throughput Screening (HTS) systems. LJL's first HTS product, Analyst, is an assay detection instrument that performs up to 70,000 screens per day and offers the ability to read results in four different assay detection modes. LJL's Acquest product, offers state-of-the-art ultra HTS formats that increase the number of screens performed. Acquest can perform up to 200,000 tests per day. LJL markets its products through a direct sales force in North America and Europe.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next